<DOC>
	<DOCNO>NCT01209507</DOCNO>
	<brief_summary>Gynecologic Oncology patient several different chemotherapy regimen , dexamethasone routinely give prevent allergic reaction chemotherapeutic agent . The common chemotherapeutic agent use paclitaxel carboplatin . This combination regimen give every three week total 5-6 dos . Each dose give administration 20 mg dexamethasone twelve hour prior morning chemotherapy . Dexamethasone use antiemetic effect , also minimize potentially fatal hypersensitivity reaction occur paclitaxel . Another commonly use chemotherapy regimens weekly cisplatin give one dose dexamethasone cervical cancer . Chronic steroid know cause adrenal suppression , know amount dexamethasone give gynecologic cancer chemotherapy regimens described cause adrenal insufficiency patient . The investigator hypothesis woman receive steroid chemotherapy may adrenal insufficiency , great normal chemotherapy-related fatigue .</brief_summary>
	<brief_title>Prevalence Study Adrenal Suppression After Corticosteroids During Chemotherapy</brief_title>
	<detailed_description>This non-blinded , non-randomized , non-interventional prospective cohort study evaluate prevalence adrenal suppression gynecologic cancer patient undergo chemotherapy regimen require concurrent dexamethasone . Women gynecologic cancer ( include cervical , endometrial , ovarian , fallopian tube , primary peritoneal cancer ) schedule begin chemotherapy standard chemotherapy regimen also receive dexamethasone . After informed consent obtain , peripheral blood sample draw time routine blood draw ( ideally fast morning ) cortisol level three different time routine care . Patients also answer quality life questionnaire time blood draws ass symptom associate treatment ( nausea , vomit , fatigue ) . A total 80 subject recruit participate . 40 subject give chemotherapy regimens receive dexamethasone three chemotherapy treatment three week cycle . 40 subject give chemotherapy regimens receive dexamethasone one chemotherapy treatment three week cycle .</detailed_description>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>1 . Patients must age great equal 18 2 . Patients histologic diagnosis cervical , endometrial , ovarian cancer receive chemotherapy 3 . Any clinical stage allow 4 . GOG performance status 0 , 1 , 2 5 . Written inform consent HIPAA authorization obtain prior initiation study procedures 1 . The presence comorbid condition know impact adrenal function , whether primary adrenal dysfunction , dysfunction due administration steroid treatment ( Addison 's Cushings disease , pituitary hypothalamic disease , systemic lupus erythematosis , rheumatoid arthritis , asthma ) 2 . Patients receive chronic pulsed steroid within past 9 month . 3 . Patients previous diagnosis adrenal suppression . 4 . Underlying psychiatric condition would , opinion investigator , preclude compliance study requirement 5 . Women pregnant eligible participate . 6 . Patients receive prior radiotherapy chemotherapy abdominal pelvic tumor exclude . Prior radiation adjuvant chemotherapy localize cancer breast , head neck , skin permit , provide complete 3 year prior registration , patient remain free recurrent metastatic disease . 7 . Patients invasive malignancy , exception nonmelanoma skin cancer , specific malignancy note , ( ) evidence cancer present within last 5 year whose previous cancer treatment contraindicate protocol exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adrenal suppression</keyword>
	<keyword>Chemotherapy fatigue</keyword>
	<keyword>Quality life</keyword>
</DOC>